Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.244 EUR -2.4% Market Closed
Market Cap: 30.4m EUR

Gensight Biologics SA
Investor Relations

GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

Show more
Loading

Earnings Calls

No Earnings Calls Available

Management

Ms. Laurence Rodriguez
CEO & Director
No Bio Available
Dr. Jose-Alain Sahel M.D., Ph.D.
Scientific Founder, Vice Chairman of Scientific Advisory Board & Board Observer
No Bio Available
Prof. Botond Roska M.D., Ph.D.
Scientific Founder & Chairman of Scientific Advisory Board
No Bio Available
Dr. Constance L. Cepko Ph.D.
Scientific Founder & Member of Scientific Advisory Board
No Bio Available
Mr. Jan Eryk Umiastowski
Chief Financial Officer
No Bio Available
Mr. Scott Jeffers
Chief Technical Officer
No Bio Available
Dr. Barrett Katz CMO, M.B.A., M.D.
Consultant
No Bio Available
Dr. Magali Taiël M.D.
Chief Medical Officer
No Bio Available

Contacts

Address
ILE-DE-FRANCE
Paris
74 Rue du Faubourg Saint-Antoine
Contacts